Theravance Biopharma, Inc.
TBPH
$8.40
$0.010.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.12% | 15.93% | 20.97% | 26.65% | 11.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.12% | 15.93% | 20.97% | 26.65% | 11.84% |
| Cost of Revenue | -7.33% | -23.40% | -27.77% | -36.00% | -35.92% |
| Gross Profit | 59.13% | 289.51% | 1,188.75% | 531.20% | 239.49% |
| SG&A Expenses | -1.81% | -6.75% | -7.95% | -0.59% | 5.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.83% | -13.42% | -16.03% | -16.32% | -14.86% |
| Operating Income | 20.90% | 38.23% | 43.36% | 44.31% | 32.19% |
| Income Before Tax | 9.45% | 30.46% | 42.91% | 50.79% | 46.92% |
| Income Tax Expenses | 99.26% | 258.88% | 601.04% | 1,981.14% | 1,048.06% |
| Earnings from Continuing Operations | -2.22% | 18.93% | 32.88% | 40.44% | 40.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.22% | 13.40% | -105.26% | -105.11% | -106.33% |
| EBIT | 20.90% | 38.23% | 43.36% | 44.31% | 32.19% |
| EBITDA | 19.89% | 38.21% | 43.24% | 45.10% | 33.18% |
| EPS Basic | -19.01% | -6.32% | -108.13% | -107.47% | -108.41% |
| Normalized Basic EPS | -0.75% | 21.85% | 26.38% | 30.75% | 24.56% |
| EPS Diluted | -19.01% | -6.32% | -108.13% | -107.47% | -108.41% |
| Normalized Diluted EPS | -0.75% | 21.85% | 26.38% | 30.75% | 24.56% |
| Average Basic Shares Outstanding | -11.75% | -18.34% | -24.27% | -26.72% | -24.81% |
| Average Diluted Shares Outstanding | -11.75% | -18.34% | -24.27% | -26.72% | -24.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
